{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:09:21Z","timestamp":1781626161969,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiovascular toxicity is a well-known complication of chemotherapy, especially doxorubicin (DXR), and irradiation of the mediastinum for classical Hodgkin lymphoma (cHL). Due to the excellent prognosis in cHL, the mortality rate in late toxicity historically exceeds that of relapse of lymphoma. This highlights the need for strategies to minimize toxicity.Our aim was to characterize the prevalence of cardiovascular diseases (CVDs) in our cohort of cHL patients treated with DXR with or without radiotherapy according to standard practice and to identify any plasma protein associations with preexisting or emerging CVD posttreatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 182 different proteins in plasma samples from 56 cHL patients and 60 controls using Olink multiplex protein panels Oncology II and Cardiovascular III. The analysis was supplemented with separate analyses of N-terminal pro-brain natriuretic peptide (NTpro-BNP), troponin I and C-reactive protein (CRP). The patient samples were prospectively collected prior to, during and after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our analysis revealed a statistically significant association between the compound endpoint of heart failure and ischemic heart disease and the protein biomarkers cysteine rich protein 61 (CYR61), glycoprotein nonmetastatic melanoma protein B (GPNMB) and activated leukocyte cell adhesion molecule (ALCAM) in samples collected after treatment for cHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This exploratory study identified three new biomarkers reflecting different biological processes associated with CVD in patients treated for cHL. Adding biomarkers to risk prediction in this population has the potential to identify patients with a high risk of cardiovascular events who need focused follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40959-025-00426-2","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T02:55:12Z","timestamp":1766717712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploratory study linking plasma proteomics to cardiotoxicity in Hodgkin lymphoma"],"prefix":"10.1186","volume":"12","author":[{"given":"Johan Mattsson","family":"Ulfstedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhild","family":"Risebro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Freyhult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Christersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlott","family":"M\u00f6rth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Kamali-Moghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Robelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Enblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Molin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"10310","key":"426_CR1","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","volume":"398","author":"P Brice","year":"2021","unstructured":"Brice P, de Kerviler E, Friedberg JW. Classical hodgkin lymphoma. Lancet. 2021;398(10310):1518\u201327. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673620322078","journal-title":"Lancet"},{"issue":"6","key":"426_CR2","doi-asserted-by":"publisher","first-page":"dju110","DOI":"10.1093\/jnci\/dju110","volume":"106","author":"K Rugbjerg","year":"2014","unstructured":"Rugbjerg K, Mellemkjaer L, Boice JD, Kober L, Ewertz M, Olsen JH. Cardiovascular disease in survivors of adolescent and young adult cancer: a Danish cohort study, 1943\u20132009. J Natl Cancer Inst. 2014;106(6):dju110. https:\/\/doi.org\/10.1093\/jnci\/dju110","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"426_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.28385","volume":"134","author":"AE Kero","year":"2014","unstructured":"Kero AE, Jarvela LS, Arola M, Malila N, Madanat-Harjuoja LM, Matomaki J, et al. Cardiovascular morbidity in long-term survivors of early-onset cancer: a population-based study. Int J Cancer. 2014;134(3):664\u201373. https:\/\/doi.org\/10.1002\/ijc.28385","journal-title":"Int J Cancer"},{"issue":"3","key":"426_CR4","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/cncr.32580","volume":"126","author":"S de Fine Licht","year":"2020","unstructured":"de Fine Licht S, Maraldo MV, Specht L, Nielsen TT, Winther JF, Rugbjerg K. Risk factors for cardiovascular disease in 5-year survivors of adolescent and young adult cancer: A Danish population-based cohort study. Cancer. 2020;126(3):659\u201369. https:\/\/doi.org\/10.1002\/cncr.32580","journal-title":"Cancer"},{"key":"426_CR5","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.3389\/fphar.2018.01262","volume":"9","author":"CG Nebigil","year":"2018","unstructured":"Nebigil CG, Desaubry L. Updates in Anthracycline-Mediated cardiotoxicity. Front Pharmacol. 2018;9:1262. https:\/\/doi.org\/10.3389\/fphar.2018.01262","journal-title":"Front Pharmacol"},{"issue":"8","key":"426_CR6","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"426_CR7","first-page":"411","volume":"6","author":"J Wojtacki","year":"2000","unstructured":"Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention\u2013review of the literature. Med Sci Monit. 2000;6(2):411\u201320.","journal-title":"Med Sci Monit"},{"key":"426_CR8","unstructured":"Hufnagle JJ, Andersen SN, Maani EV. Radiation Therapy Induced Cardiac Toxicity. StatPearls. Treasure Island (FL)2021 :StatPearls Publishing; 2025. 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554453\/"},{"issue":"5","key":"426_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11883-017-0658-x","volume":"19","author":"D Raghunathan","year":"2017","unstructured":"Raghunathan D, Khilji MI, Hassan SA, Yusuf SW. Radiation-Induced cardiovascular disease. Curr Atheroscler Rep. 2017;19(5):22. https:\/\/doi.org\/10.1007\/s11883-017-0658-x","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"426_CR10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.5603\/cj.a2018.0120","volume":"27","author":"I Nabialek-Trojanowska","year":"2020","unstructured":"Nabialek-Trojanowska I, Lewicka E, Wrona A, Kaleta AM, Lewicka-Potocka Z, Raczak G, et al. Cardiovascular complications after radiotherapy. Cardiol J. 2020;27(6):836\u201347. https:\/\/doi.org\/10.5603\/cj.a2018.0120","journal-title":"Cardiol J"},{"issue":"2","key":"426_CR11","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/hon.2715","volume":"38","author":"E Galli","year":"2020","unstructured":"Galli E, Cuccaro A, Maiolo E, Bellesi S, D\u2019Alo F, Fusco D, et al. Comorbidity assessment to determine prognosis in older adult patients with classical hodgkin lymphoma. Hematol Oncol. 2020;38(2):153\u201361. https:\/\/doi.org\/10.1002\/hon.2715","journal-title":"Hematol Oncol"},{"issue":"2","key":"426_CR12","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jaccao.2021.05.002","volume":"3","author":"KK Ness","year":"2021","unstructured":"Ness KK. The need for an early biomarker of cardiovascular disease in survivors of hodgkin lymphoma. JACC CardioOncol. 2021 15;3(2):274\u20136. https:\/\/doi.org\/10.1016\/j.jaccao.2021.05.002","journal-title":"JACC CardioOncol"},{"issue":"1","key":"426_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40959-021-00092-0","volume":"7","author":"C Morth","year":"2021","unstructured":"Morth C, Sabaa AA, Freyhult E, Christersson C, Hashemi J, Hashemi N, et al. Plasma proteome profiling of cardiotoxicity in patients with diffuse large B-cell lymphoma. Cardiooncology. 2021;7(1):6. https:\/\/doi.org\/10.1186\/s40959-021-00092-0","journal-title":"Cardiooncology"},{"issue":"2","key":"426_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/0284186x.2017.1337926","volume":"57","author":"B Glimelius","year":"2018","unstructured":"Glimelius B, Melin B, Enblad G, Alafuzoff I, Beskow A, Ahlstrom H, et al. U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. Acta Oncol. 2018;57(2):187\u201394. https:\/\/doi.org\/10.1080\/0284186x.2017.1337926","journal-title":"Acta Oncol"},{"issue":"2","key":"426_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10654-013-9787-x","volume":"28","author":"L Lind","year":"2013","unstructured":"Lind L, Elmstahl S, Bergman E, Englund M, Lindberg E, Michaelsson K, et al. EpiHealth: a large population-based cohort study for investigation of gene-lifestyle interactions in the pathogenesis of common diseases. Eur J Epidemiol. 2013;28(2):189\u201397. https:\/\/doi.org\/10.1007\/s10654-013-9787-x","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"426_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3109\/00365513.2011.557086","volume":"71","author":"J Bjork","year":"2011","unstructured":"Bjork J, Grubb A, Sterner G, Nyman U. Revised equations for estimating glomerular filtration rate based on the Lund-Malmo study cohort. Scand J Clin Lab Invest. 2011;71(3):232\u20139. https:\/\/doi.org\/10.3109\/00365513.2011.557086","journal-title":"Scand J Clin Lab Invest"},{"issue":"6","key":"426_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1515\/cclm-2013-0741","volume":"52","author":"U Nyman","year":"2014","unstructured":"Nyman U, Grubb A, Larsson A, Hansson LO, Flodin M, Nordin G, et al. The revised Lund-Malmo GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. Clin Chem Lab Med. 2014;52(6):815\u201324. https:\/\/doi.org\/10.1515\/cclm-2013-0741","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"426_CR18","doi-asserted-by":"publisher","first-page":"e95192","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9(4):e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192","journal-title":"PLoS ONE"},{"issue":"5","key":"426_CR19","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jaccao.2020.08.014","volume":"2","author":"JA Alvarez-Cardona","year":"2020","unstructured":"Alvarez-Cardona JA, Zhang KW, Mitchell JD, Zaha VG, Fisch MJ, Lenihan DJ. Cardiac biomarkers during cancer therapy: practical applications for Cardio-Oncology. JACC CardioOncol. 2020;2(5):791\u20134. https:\/\/doi.org\/10.1016\/j.jaccao.2020.08.014","journal-title":"JACC CardioOncol"},{"issue":"3","key":"426_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","volume":"13","author":"K Ananthan","year":"2020","unstructured":"Ananthan K, Lyon AR. The role of biomarkers in Cardio-Oncology. J Cardiovasc Transl Res. 2020;13(3):431\u201350. https:\/\/doi.org\/10.1007\/s12265-020-10042-3","journal-title":"J Cardiovasc Transl Res"},{"issue":"12","key":"426_CR21","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1080\/0284186X.2019.1648861","volume":"58","author":"D Schoormans","year":"2019","unstructured":"Schoormans D, Husson O, Oerlemans S, Ezendam N, Mols F. Having co-morbid cardiovascular disease at time of cancer diagnosis: already one step behind when it comes to HRQoL? Acta Oncol. 2019;58(12):1684\u201391. https:\/\/doi.org\/10.1080\/0284186x.2019.1648861","journal-title":"Acta Oncol"},{"issue":"1","key":"426_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12885-019-6472-9","volume":"20","author":"H Fowler","year":"2020","unstructured":"Fowler H, Belot A, Ellis L, Maringe C, Luque-Fernandez MA, Njagi EN, et al. Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers. BMC Cancer. 2020;20(1):2. https:\/\/doi.org\/10.1186\/s12885-019-6472-9","journal-title":"BMC Cancer"},{"issue":"7","key":"426_CR23","doi-asserted-by":"publisher","first-page":"E255","DOI":"10.1002\/ajh.26558","volume":"97","author":"K Larsson","year":"2022","unstructured":"Larsson K, Soderling J, Hoglund M, Glimelius I, Mattsson M. Cardiovascular disease in patients with chronic lymphocytic leukemia: A Swedish nationwide register study with matched comparators. Am J Hematol. 2022;97(7):E255\u20137. https:\/\/doi.org\/10.1002\/ajh.26558","journal-title":"Am J Hematol"},{"issue":"Pt 23","key":"426_CR24","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1242\/jcs.03270","volume":"119","author":"A Leask","year":"2006","unstructured":"Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci. 2006;119(Pt 23):4803\u201310. https:\/\/doi.org\/10.1242\/jcs.03270","journal-title":"J Cell Sci"},{"issue":"10","key":"426_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.5483\/BMBRep.2018.51.10.192","volume":"51","author":"H Kim","year":"2018","unstructured":"Kim H, Son S, Shin I. Role of the CCN protein family in cancer. BMB Rep. 2018;51(10):486\u201392. https:\/\/doi.org\/10.5483\/bmbrep.2018.51.10.192","journal-title":"BMB Rep"},{"issue":"19","key":"426_CR26","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1007\/s00018-011-0778-3","volume":"68","author":"LF Lau","year":"2011","unstructured":"Lau LF. CCN1\/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci. 2011;68(19):3149\u201363. https:\/\/doi.org\/10.1007\/s00018-011-0778-3","journal-title":"Cell Mol Life Sci"},{"issue":"1\u20132","key":"426_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0169-328X(02)00135-3","volume":"101","author":"DA Schwarz","year":"2002","unstructured":"Schwarz DA, Barry G, Mackay KB, Manu F, Naeve GS, Vana AM, et al. Identification of differentially expressed genes induced by transient ischemic stroke. Brain Res Mol Brain Res. 2002;101(1\u20132):12\u201322.","journal-title":"Brain Res Mol Brain Res"},{"issue":"4","key":"426_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2217\/bmm-2017-0390","volume":"12","author":"J Deng","year":"2018","unstructured":"Deng J, Qian X, Li J, Li Y, Li Y, Luo Y. Evaluation of serum cysteine-rich protein 61 levels in patients with coronary artery disease. Biomark Med. 2018;12(4):329\u201339. https:\/\/doi.org\/10.2217\/bmm-2017-0390","journal-title":"Biomark Med"},{"issue":"2","key":"426_CR29","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1161\/01.CIR.0000021426.87274.62","volume":"106","author":"A Hilfiker","year":"2002","unstructured":"Hilfiker A, Hilfiker-Kleiner D, Fuchs M, Kaminski K, Lichtenberg A, Rothkotter HJ, et al. Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. Circulation. 2002;106(2):254\u201360. https:\/\/doi.org\/10.1161\/01.cir.0000021426.87274.62","journal-title":"Circulation"},{"issue":"47","key":"426_CR30","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1093\/eurheartj\/ehx640","volume":"38","author":"R Klingenberg","year":"2017","unstructured":"Klingenberg R, Aghlmandi S, Liebetrau C, Raber L, Gencer B, Nanchen D, et al. Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. Eur Heart J. 2017;38(47):3493\u2013502. https:\/\/doi.org\/10.1093\/eurheartj\/ehx640","journal-title":"Eur Heart J"},{"key":"426_CR31","doi-asserted-by":"publisher","unstructured":"Zhao J, Zhang C, Liu J, Zhang L, Cao Y, Wu D, et al. Prognostic significance of serum Cysteine-Rich protein 61 in patients with acute heart failure. Cell Physiol Biochem. 2018;48(3):1177\u201387. https:\/\/doi.org\/10.1159\/000491984","DOI":"10.1159\/000491984"},{"key":"426_CR32","doi-asserted-by":"publisher","unstructured":"Liu C, Liang W, He X, Owusu-Agyeman M, Wu Z, Zhou Y, et al. Prognostic value of Cysteine-Rich protein 61 combined with N-Terminal Pro-B-Type natriuretic peptide for mortality in acute heart failure patients with and without chronic kidney disease. Cardiorenal Med. 2020;10(1):11\u201321. https:\/\/doi.org\/10.1159\/000501929","DOI":"10.1159\/000501929"},{"key":"426_CR33","doi-asserted-by":"publisher","unstructured":"Yu Y, Gao Y, Wang H, Huang L, Qin J, Guo R, et al. The matrix protein CCN1 (CYR61) promotes proliferation, migration and tube formation of endothelial progenitor cells. Exp Cell Res. 2008;314(17):3198\u2013208. https:\/\/doi.org\/10.1016\/j.yexcr.2008.08.001","DOI":"10.1016\/j.yexcr.2008.08.001"},{"key":"426_CR34","doi-asserted-by":"publisher","unstructured":"Saade M, Araujo de Souza G, Scavone C, Kinoshita PF. The role of GPNMB in inflammation. Front Immunol. 2021;12:674739. https:\/\/doi.org\/10.3389\/fimmu.2021.674739","DOI":"10.3389\/fimmu.2021.674739"},{"key":"426_CR35","doi-asserted-by":"publisher","unstructured":"Nickl B, Qadri F, Bader M. Anti-inflammatory role of Gpnmb in adipose tissue of mice. Sci Rep. 2021;11(1):19614. https:\/\/doi.org\/10.1038\/s41598-021-99090-6","DOI":"10.1038\/s41598-021-99090-6"},{"key":"426_CR36","doi-asserted-by":"publisher","unstructured":"Jarve A, Muhlstedt S, Qadri F, Nickl B, Schulz H, Hubner N, et al. Adverse left ventricular remodeling by glycoprotein nonmetastatic melanoma protein B in myocardial infarction. FASEB J. 2017;31(2):556\u201368. https:\/\/doi.org\/10.1096\/fj.201600613r","DOI":"10.1096\/fj.201600613r"},{"key":"426_CR37","doi-asserted-by":"publisher","unstructured":"Nakano Y, Suzuki Y, Takagi T, Kitashoji A, Ono Y, Tsuruma K, et al. Glycoprotein nonmetastatic melanoma protein B (GPNMB) as a novel neuroprotective factor in cerebral ischemia-reperfusion injury. Neuroscience. 2014;277:123\u201331. https:\/\/doi.org\/10.1016\/j.neuroscience.2014.06.065","DOI":"10.1016\/j.neuroscience.2014.06.065"},{"key":"426_CR38","doi-asserted-by":"publisher","unstructured":"Xu J, Jullig M, Middleditch MJ, Cooper GJ. Modelling atherosclerosis by proteomics: molecular changes in the ascending aortas of cholesterol-fed rabbits. Atherosclerosis. 2015;242(1):268\u201376. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.07.001","DOI":"10.1016\/j.atherosclerosis.2015.07.001"},{"key":"426_CR39","doi-asserted-by":"publisher","unstructured":"Kong X, Sawalha AH. Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex. Ann Rheum Dis. 2019;78(10):1388\u201397. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215567","DOI":"10.1136\/annrheumdis-2019-215567"},{"key":"426_CR40","doi-asserted-by":"publisher","unstructured":"Bowen MA, Patel DD, Li X, Modrell B, Malacko AR, Wang WC, et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med. 1995;181(6):2213\u201320. https:\/\/doi.org\/10.1084\/jem.181.6.2213","DOI":"10.1084\/jem.181.6.2213"},{"key":"426_CR41","doi-asserted-by":"publisher","unstructured":"Ohneda O, Ohneda K, Arai F, Lee J, Miyamoto T, Fukushima Y, et al. ALCAM (CD166): its role in hematopoietic and endothelial development. Blood. 2001;98(7):2134\u201342. https:\/\/doi.org\/10.1182\/blood.v98.7.2134","DOI":"10.1182\/blood.v98.7.2134"},{"key":"426_CR42","doi-asserted-by":"publisher","unstructured":"Delgado C, Bu L, Zhang J, Liu FY, Sall J, Liang FX et al. Neural cell adhesion molecule is required for ventricular conduction system development. Development. 2021;148(11). https:\/\/doi.org\/10.1242\/dev.199431","DOI":"10.1242\/dev.199431"},{"key":"426_CR43","doi-asserted-by":"publisher","unstructured":"Darvishi B, Boroumandieh S, Majidzadeh AK, Salehi M, Jafari F, Farahmand L. The role of activated leukocyte cell adhesion molecule (ALCAM) in cancer progression, invasion, metastasis and recurrence: A novel cancer stem cell marker and tumor-specific prognostic marker. Exp Mol Pathol. 2020;115:104443. https:\/\/doi.org\/10.1016\/j.yexmp.2020.104443","DOI":"10.1016\/j.yexmp.2020.104443"},{"key":"426_CR44","doi-asserted-by":"publisher","unstructured":"Masedunskas A, King JA, Tan F, Cochran R, Stevens T, Sviridov D, et al. Activated leukocyte cell adhesion molecule is a component of the endothelial junction involved in transendothelial monocyte migration. FEBS Lett. 2006;580(11):2637\u201345. https:\/\/doi.org\/10.1016\/j.febslet.2006.04.013","DOI":"10.1016\/j.febslet.2006.04.013"},{"key":"426_CR45","doi-asserted-by":"publisher","unstructured":"Lyck R, Lecuyer MA, Abadier M, Wyss CB, Matti C, Rosito M, et al. ALCAM (CD166) is involved in extravasation of monocytes rather than T cells across the blood-brain barrier. J Cereb Blood Flow Metab. 2017;37(8):2894\u2013909. https:\/\/doi.org\/10.1177\/0271678x16678639","DOI":"10.1177\/0271678x16678639"},{"key":"426_CR46","doi-asserted-by":"publisher","unstructured":"Smedbakken L, Jensen JK, Hallen J, Atar D, Januzzi JL, Halvorsen B, et al. Activated leukocyte cell adhesion molecule and prognosis in acute ischemic stroke. Stroke. 2011;42(9):2453\u20138. https:\/\/doi.org\/10.1161\/strokeaha.110.612440","DOI":"10.1161\/strokeaha.110.612440"},{"key":"426_CR47","doi-asserted-by":"publisher","unstructured":"Berg J, Halvorsen AR, Bengtson MB, Tasken KA, Maelandsmo GM, Yndestad A, et al. Levels and prognostic impact of Circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease. BMC Cancer. 2018;18(1):739. https:\/\/doi.org\/10.1186\/s12885-018-4659-0","DOI":"10.1186\/s12885-018-4659-0"},{"key":"426_CR48","doi-asserted-by":"publisher","unstructured":"Ueland T, Akerblom A, Ghukasyan T, Michelsen AE, Becker RC, Bertilsson M, et al. ALCAM predicts future cardiovascular death in acute coronary syndromes: insights from the PLATO trial. Atherosclerosis. 2020;293:35\u201341. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.11.031","DOI":"10.1016\/j.atherosclerosis.2019.11.031"},{"issue":"8","key":"426_CR49","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1080\/10428190802140873","volume":"49","author":"S Myrehaug","year":"2008","unstructured":"Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, et al. Cardiac morbidity following modern treatment for hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486\u201393. https:\/\/doi.org\/10.1080\/10428190802140873","journal-title":"Leuk Lymphoma"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00426-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00426-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00426-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:48:22Z","timestamp":1781624902000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-025-00426-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["426"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00426-2","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EDTA plasma samples were released from the U-CAN biobank for the plasma proteome analysis under ethical approval (dnr. 2013\/059 and dnr. 2014\/233). Data collection in the EpiHealth study and usage of the material in this project was approved by the Ethics Committee of Uppsala (dnr. 2010\/402: 2010-12-01, 2011-11-17, dnr. 2015\/179).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Christina Christersson: Speaker fees from Novartis.Gunilla Enblad: Scientific advisor for Sprint Bioscience, XNK Therapeutics, and Elicera. Avisory board of Gilead. Speaker fees from Pierre Fabre and Roche.Daniel Molin: Previously speaker fees from Roche, Merck, Bristol-Myers Squibb, and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}